Turn Biotechnologies Completes Latest Round Of Funding

Apr 28, 2021•over 4 years ago

SeoulBiotechnologyHealth Care

Description

Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest round of funding. The company has the support of investors focused on identifying and backing enterprises that have the potential to change the world with their disruptive technologies.

Company Information

Company

Turn Biotechnologies

Location

Seoul, Seoul, South Korea

About

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERATM, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, and heal or regenerate tissue and will help to fight incurable chronic diseases. Turn Bio's technology provides a platform from which to attack a variety of now incurable chronic diseases. The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see turn.bio or contact Jim Martinez, rightstorygroup / jim@rightstorygroup.com or (312) 543-9026.